Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 42

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 42
---
8% of our CEO’s target total direct compensation in 2024, while variable pay, consisting of annual incentives in the form of an annual bonus program and long-term incentives in the form of equity awards, made up 91.2% of his target total direct compensation. Similar allocations applied to our other executive officers, including our other Named Executive Officers. The following chart shows the percentages of target variable pay versus target fixed pay for our CEO and our other Named Executive Officers in 2024:

| Named Executive Officer        |     | Title                                 |     | Total Pay (2024) |     | Percentage of Pay (Fixed) |     | Percentage of Pay (Variable) |
| Carsten Brunn, Ph.D.           |     | President and Chief Executive Officer |     |       $7,314,211 |     | 8.8%                      |     | 91.2%                        |
| Blaine Davis                   |     | Chief Financial Officer               |     |       $3,971,412 |     | 11.6%                     |     | 88.4%                        |
| Metin Kurtoglu, M.D., Ph.D.(1) |     | Chief Technology Officer              |     |       $2,713,064 |     | 15.9%                     |     | 84.1%                        |
| Christopher Jewell, Ph.D.(2)   |     | Chief Scientific Officer              |     |       $1,687,754 |     | 24.4%                     |     | 75.6%                        |

(1) Dr. Kurtoglu was appointed Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(2) Dr. Jewell was appointed Chief Scientific Officer on November 13, 2023.

#### Merger
On November 13, 2023 we entered into the Merger Agreement, pursuant to which Sakura Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of ours (“First Merger Sub”) merged with and into Old Cartesian, pursuant to which Old Cartesian was the surviving corporation and became a wholly owned subsidiary of ours (the “First Merger”). Immediately following the First Merger, Old Cartesian merged with and into Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ours (“Second Merger Sub”), pursuant to which Second Merger Sub